Osteopontin Expression and Prognostic Significance in Non–Small Cell Lung Cancer

Purpose: The survival rate of non–small cell lung cancer patients is very low, and knowledge of predictors of outcome is inadequate. To improve the curability of lung cancer, we need to identify new specific molecules involved in tumorigenesis and progression. The purpose of this study was to better...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2005-09, Vol.11 (18), p.6459-6465
Main Authors: DONATI, Valentina, BOLDRINI, Laura, FONTANINI, Gabriella, DELL'OMODARME, Matteo, PRATI, Maria C, FAVIANA, Pinuccia, CAMACCI, Tiziano, LUCCHI, Marco, MUSSI, Alfredo, SANTORO, Massimo, BASOLO, Fulvio
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic agents
Biological and medical sciences
Carcinoma, Non-Small-Cell Lung - metabolism
Carcinoma, Non-Small-Cell Lung - pathology
disease-free survival
Female
Humans
Immunohistochemistry
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Male
Medical sciences
Middle Aged
Multivariate Analysis
Neoplasm Staging
non–small cell lung cancer (NSCLC)
Osteopontin
overall survival
Pharmacology. Drug treatments
Pneumology
Prognosis
Sialoglycoproteins - biosynthesis
Survival Analysis
Tumors of the respiratory system and mediastinum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: The survival rate of non–small cell lung cancer patients is very low, and knowledge of predictors of outcome is inadequate. To improve the curability of lung cancer, we need to identify new specific molecules involved in tumorigenesis and progression. The purpose of this study was to better define the role of osteopontin in non–small cell lung cancer biology by determining its prognostic significance. Experimental Design: Osteopontin expression was evaluated by immunohistochemistry, as percentage of neoplastic cells with cytoplasmic immunoreactivity, in a wide series of patients with stage I-IIIA non–small cell lung cancer (207 cases). The median value of this series (20% of positive cells) was used as the cutoff value to distinguish tumors with low (
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-05-0541